FURX News Alert Furiex Pharmaceuticals (FURX) 104.77 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Furiex Pharmaceuticals (FURX) 104.77 $FURX

UNC-Chapel Hill Eshelman School of Pharmacy Receives $100 Million Commitment - the Largest from an Individual in the University's History - from Alumnus Fred Eshelman
PR Newswire - Wed Dec 03, 1:00PM CST
The University of North Carolina at Chapel Hill today announced a $100 million commitment to the UNC Eshelman School of Pharmacy from Fred Eshelman, a 1972 graduate of the school, founder and former CEO of Pharmaceutical Product Development and founding chairman of Furiex Pharmaceuticals. The school was named for Eshelman in 2008.
FURX: 104.77 (-1.41)

Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.08 (+0.12), FURX: 104.77 (-1.41), SYN: 1.46 (-0.07), IRWD: 14.57 (+0.25), LXRX: 0.90 (+0.02), AZN: 70.44 (+0.26), TEVA: 57.09 (+0.33)

Synergy Pharma presents plecanatide IBS-C clinical trial results
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 9:11AM CDT

FURX: 104.77 (-1.41), SGYP: 3.08 (+0.12), ACT: 254.20 (-1.68), IRWD: 14.57 (+0.25), LXRX: 0.90 (+0.02), SLXP: 114.92 (-1.18), ARDX: 20.97 (-1.74)

Premature Ejaculation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Wed Sep 24, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9p25qq/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - SK Chemicals Co., Ltd. - Yungjin Pharm Ind. Co., Ltd. - Plethora Solutions Holdings plc - NeuroHealing Pharmaceuticals Inc. - Furiex Pharmaceuticals, Inc. - Dong-A Socio Group Drug Profiles - tramadol hydrochloride - (lidocaine prilocaine) - dapoxetine hydrochloride - tramadol hydrochloride - onabotulinumtoxin A - DA-8031 - IX-01 - modafinil - NCE-405 - YPE-1706 For more information visit http://www.researchandmarkets.com/research/9p25qq/premature
FURX: 104.77 (-1.41), AGN: 210.12 (+0.95)

Actavis buys Furiex Pharmaceuticals in all-cash transaction
M2 - Thu Jul 03, 6:31AM CDT
Pharmaceutical company Actavis (NYSE:ACT) stated on Wednesday that its Forest Laboratories subsidiary has closed the acquisition of Furiex Pharmaceuticals (NasdaqGS:FURX) in USD1.1bn in cash.
FURX: 104.77 (-1.41), ACT: 254.20 (-1.68)

Salix Pharmaceuticals Surges on Positive IBS Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 5:15PM CDT
Salix Pharmaceuticals, Ltd.'s (SLXP) announced encouraging data from a phase III study on Xifaxan 550 mg.
FURX: 104.77 (-1.41), MDCO: 27.06 (+0.21), HZNP: 12.38 (+0.13), SLXP: 114.92 (-1.18)

Actavis Completes Acquisition of Furiex Pharmaceuticals
PR Newswire - Wed Jul 02, 7:46AM CDT
Actavis plc (NYSE: ACT) today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.
FURX: 104.77 (-1.41), ACT: 254.20 (-1.68), FRX: 99.00 (-0.77)

Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger
Business Wire - Tue Jul 01, 2:15PM CDT
The stockholders of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) voted today at a special meeting of stockholders to adopt the previously announced agreement and plan of merger, dated as of April 27, 2014, providing for the merger of Furiex with an entity now controlled by Forest Laboratories, LLC, a subsidiary of Actavis plc (NYSE: ACT). Actavis completed its acquisition of Forest Laboratories, Inc. on July 1, 2014. The votes cast by Furiex's stockholders in favor of the proposal to adopt the merger agreement represented approximately 79.85% of Furiex's issued and outstanding common stock entitled to vote as of May 29, 2014, the record date for the special meeting.
FURX: 104.77 (-1.41), ACT: 254.20 (-1.68), FRX: 99.00 (-0.77)

Insider Trading Alert - FURX, EGP And FLT Traded By Insiders
at The Street - Fri Jun 13, 9:13AM CDT
Stocks with insider trader activity include FURX, EGP and FLT
FURX: 104.77 (-1.41), EGP: 64.03 (+0.03), FLT: 149.17 (-0.93)

Approvals, Agreements, Name Change, and Partnerships - Analyst Notes on Johnson & Johnson, Furiex Pharmaceuticals, Select Medical, CTI and Hill-Rom
PR Newswire - Fri Jun 13, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), Select Medical Holdings Corporation (NYSE: SEM), CTI BioPharma Corp. (NASDAQ: CTIC) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3701-100free.
FURX: 104.77 (-1.41), JNJ: 104.59 (+0.31), CTIC: 2.36 (+0.05), SEM: 14.67 (+0.27), HRC: 46.04 (+0.41)

Regal Entertainment Group Announces Proposed Senior Notes Offering
Business Wire - Tue Feb 25, 6:49AM CST
Regal Entertainment Group ("Regal" or the "Company" (NYSE:RGC) announced today that it plans to offer senior notes due 2022 (the "Notes" in a registered offering. The principal amount, interest rate and certain other terms of the offering will be determined at the time of pricing.
FURX: 104.77 (-1.41), RGC: 21.20 (+0.09)

Lupus LA/Cedars-Sinai Rheumatology Fellowship Program Names Dr. Vaneet Sandhu As Fellow
PR Newswire - Thu Jan 30, 6:00AM CST
Lupus LA and Cedars-Sinai Medical Center have joined together to support a two-year fellowship and have named Dr. Vaneet Sandhu as the Lupus LA/Cedars-Sinai Fellow. Lupus is a chronic autoimmune disease that can affect virtually any organ of the body, and has no known cause or cure. Dr. Sandhu will be joining a 'dream team' of lupus researchers at Cedars-Sinai, known in the medical community for cutting edge research and world-renowned patient care. The Lupus LA/Cedars-Sinai Rheumatology Fellowship was funded by Lupus LA.
FURX: 104.77 (-1.41), SNTA: 2.63 (+0.02), PBH: 34.02 (+0.06), JAZZ: 165.33 (+1.83), SNSS: 2.48 (-0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 34

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 112

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 268

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading

Top 5 Most Recently Viewed Articles

Future of Crypto: Brian Armstrong on Innovative Payment Solutions

Updated Category News Views 292

Coinbase's Vision for Payments in the Crypto World Brian Armstrong, the CEO of Coinbase Global Inc. (NASDAQ: COIN), is optimistic about the role of payments as a transformative use case within the cryptocurrency landscape. In a recent discussion, he articulated how he believes this sector will significantly evolve, particularly in terms of integrating stablecoins into...

Continue Reading
Veeva Basics Empowering Biotechs to Enhance Efficiency and Growth

Updated Category News Views 185

Veeva Basics Revolutionizes Biotech Operations In today's fast-paced biotech landscape, efficient operations are crucial. Veeva Systems (NYSE: VEEV) has introduced Veeva Basics, a solution now adopted by over 100 emerging biotechs. With this innovative approach, these companies can simplify and standardize their operations, allowing them to focus on what truly matters:...

Continue Reading
Exploring the Rise of Small-Cap Stocks: A 2024 Overview

Updated Category News Views 613

Small-Cap Stocks Lead 2024 Gains In the vibrant market of 2024, small-cap stocks have shined brighter than ever, showcasing remarkable performance that has left traditional blue-chip stocks in their wake. While larger, well-known companies often dominate discussions, smaller firms are making headlines with exhilarating returns. Remarkable Returns in the Market This year,...

Continue Reading
Ridge Street Capital Signs Significant Growth in Lending Sector

Updated Category News Views 206

Ridge Street Capital's Impressive Growth in Investment Lending Ridge Street Capital, a dynamic private lending firm, is celebrating a remarkable achievement in its operation, reporting over 150% growth from one year to the next. This impressive advancement marks the firm as a key player in investment property financing, primarily due to its tailored approach and...

Continue Reading
Kuehn Law Advocates for Sarepta Therapeutics Shareholders

Updated Category News Views 153

Kuehn Law Advocates for Sarepta Therapeutics Shareholders Kuehn Law, PLLC, a law firm dedicated to shareholder litigation, is reaching out to investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) regarding pressing concerns that have surfaced about the company's internal practices. Recent investigations suggest that certain officers and directors possibly did not uphold...

Continue Reading